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Multiple  host  genes have been  shown to influence the course of erythroleukemia 
induced by Friend virus  (FV) 1 (1). Two H-2-associated genes and a  non-H-2-1inked 
gene are  required  for recovery from FV leukemia  (2,  3).  The non-H-2-1inked gene, 
Rfv-3, appears to influence the production of anti-FV antibody independent  of the 
H-2 genotype (3). Although mice of the Rfv-3  r/~ genotype produce high levels of anti- 
FV antibody, they fail  to recover from FV-induced leukemia unless the appropriate 
H-2-associated genes are present  (3). Thus, FV leukemia cells  continue to proliferate 
even  in  the  presence  of anti-FV  antibody,  possibly  because  of their  resistance  to 
antibody-complement-mediated lysis  (4). Furthermore, FV leukemic spleen cells  late 
in the disease express decreased amounts of FV cell surface antigens and release less 
infectious virus than leukemic spleen cells  early in the course of the disease  (5). The 
low levels of FV cell surface antigens and infectious virus observed in mice with anti- 
FV antibody were found to be reversible after transfer of leukemic spleen cells  into 
nonimmune  animals  (5). Therefore,  anti-FV  antibody  appeared  to  play  a  role  in 
altering the expression of viral antigens and infectious virus release in these cells.  To 
examine  further  this  phenomenon,  we  studied  the  expression  of  individual  FV- 
encoded proteins  in  FV  leukemic spleen  cells  at  various times  in  the course of the 
disease.  Our results indicated that the presence of anti-FV antibody late in the disease 
was associated with a decreased expression of Friend helper virus (F-MuLV)-encoded 
intracellular  and  cell  surface  proteins,  whereas  the  expression  of the  replication- 
defective spleen  focus-forming virus  (SFFV)-encoded proteins appeared  to be mini- 
mally altered. This selective loss of F-MuLV proteins appeared to correlate with the 
specficity of the mouse anti-FV antibody that was found to recognize F-MuLV but 
not  SFFV-specific proteins.  In  addition,  we  have  also  demonstrated  a  new  gp70 
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molecule on the surface of FV leukemic spleen cells late in the disease. This molecule 
differs from gp70 in the ecotropic Friend virus, which was inoculated into these mice, 
in  that  it  shares  strong cross-reactivity with  Friend mink cell  focus-inducing virus 
(FMCF). The potential importance of this recombinant viral protein to the mainte- 
nance of the malignant phenotype is discussed. 
Materials and Methods 
Animals.  C57BL/10Sn, B10.A, A.BY, and A/WySn mice were purchased from The Jackson 
Laboratory, Bar Harbor, Maine. F1 hybrids were bred at the Rocky Mountain Laboratories, 
Hamilton, Mont. Mice used in all experiments were between 2 and 4 mo of age. 
Cells and Virus.  The B-tropic strain of Friend virus complex (FV) was obtained from Dr. F. 
Lilly, Albert Einstein School of Medicine, Bronx, N.  Y. The virus stocks used for inoculation 
were prepared  in (C57BL/10Sn x  A.BY)F1 mice and assayed as  previously reported  (2). A 
mink lung cell  line producing xenotropic murine leukemia virus (xenotropic MuLV)  from 
C57L mice was obtained from Dr. J.  Levy,  University of California, San Francisco, Calif. A 
mink lung cell  line producing BALB IU-1  (6)  xenotropic MuLV was obtained from Dr.  M. 
Cloyd, Rocky Mountain Laboratories, Hamilton, Mont. FMCF-producing mink lung cell lines 
were  provided  by  Dr.  D.  Troxler  (FMCF-Troxler strain)  (7), National  Cancer  Institute, 
Bethesda, Md., and Dr. M. Cloyd (FMCF-Ishimoto strain) (6). The mink lung cell lines were 
grown in RPMI 1640 media supplemented with 2% fetal calf serum (FCS).  SC-1 cells (8) were 
maintained and infected with FV or the F-MuLV helper virus alone as previously reported (9). 
The erythroleukemia cell lines, Y57  (clone 2C) and AA41, have been described previously (4, 
10). 
Early and Late Leukemic Spleen Cells.  Leukemic spleen cells were obtained from  (B10.A  × 
A/WySn)F1 mice given 5,000  focus-forming units (FFU) of FV intravenously. Large  (>1  g) 
leukemic spleens were removed, and single cell suspensions were prepared in phosphate-buffered 
balanced salt solution (PBBS)  8-10 d after virus inoculation (early leukemic spleen cells) and 
30-60 d after virus inoculation (late leukemic spleen cells) (4). 
Antisera.  Anti-FV antisera were prepared in C57BL/10Sn and  (C57BL/10Sn ×  A.BY)F, 
mice  repeatedly  immunized with  30  ×  106  viable  early  FV  leukemic  spleen  cells  from 
(C57BL/IOSn ×  A.BY)F1 mice. Antisera prepared in both strains of mice gave identical results 
when used to immunoprecipitate  radiolabeled spleen cell lysates. Furthermore, anti-FV antisera 
prepared in C57BL/10Sn mice exhibited no detectable cell surface reactivity against normal 
spleen cells  from  (C57BL/10Sn ×  A.BY)FI  or  (B10.A  ×  A/WySn)F, mice. Antisera to  the 
purified  Rauscher  leukemia virus  (RLV)  proteins were  obtained from  the  Viral  Oncology 
Program, National Cancer Institute. The following lots were used: anti-gp70, 5S-167, anti-p 12, 
5S-37,  and anti-p30, 2S-658.  Rabbit anti-FMCF antiserum was  provided by Dr.  M.  Cloyd. 
This antiserum was prepared by injecting viable FMCF-infected SIRC cells intravenously into 
New Zealand white rabbits. 
Antibody and Complement (C)  Cytotoxicity Assay and Quantitative Absorption.  Antibody and C- 
mediated ~'Cr release cytotoxicity assay was performed and calculated as previously described 
(11). Briefly, 0.085 ml of a dilution of the antiserum at the plateau of cytotoxicity was absorbed 
with 0.5 X 106-40 ×  106 washed cells at 0°C for 60 min. The absorbing cells were pelleted for 
10 min at 800 g, and the supernate was tested in triplicate in the 51Cr release cytotoxicity assay. 
Radioimmunoassay (RIA).  This assay is described in detail in a previous report (12). Purified 
rabbit anti-RLV gp70 serum and rabbit anti-RLV-pl2 serum, as well  as the purified RLV 
proteins, p12 and gp70, were kindly provided by Dr. J. Ihle, Frederick Cancer Research Center, 
Frederick, Md. The purified proteins were iodinated with 12sI using chloramine T. Initially, 
0.11  ml of antiserum, diluted to the point that  it  precipitated 50%  of labeled antigen, was 
mixed with increasing numbers of leukemic or normal spleen cells. After a  1-h incubation at 
4°C, the cells were removed by centrifugation, and the absorbed antiserum was tested for its 
ability to precipitate 125I-labeled antigen. The antiserum was incubated with a known amount 
of 12si antigen, followed  by precipitation of the antibody-bound antigen with  10%  (vol:vol) 
formalin-fixed Staphylococcus aureus Cowan I strain. The percentage of antigen bound was then 
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Membrane Immunofluorescence.  We have described the details of this assay previously (13). To 
remove erythrocytes, spleen cells were treated with 0.83%  NH4CI buffered with 0.017 M  Tris- 
HCI, pH  7.3  (4).  Washing buffer was PBBS with 0.01  M  NAN3. Approximately 10  o washed 
viable spleen cells were incubated with 0.05 ml of undiluted tissue culture supernate containing 
monoclonal antibody for 30 min at 4°C. Antibodies used were: 48, anti-F-MuLV gp70 and 34, 
anti-FMR p15 (13). After two washes with buffer, the cells were then incubated with 0.005 ml 
of fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse immunoglobulin (Ig) (lot 73S- 
000004;  Biological Carcinogenesis Branch, National Cancer Institute). Cells were washed twice 
with buffer, resuspended in 2% formalin (vol:vol) in PBS, and viewed under a Lietz Orthoplan 
microscope (E. Leitz, Inc., Roekleigh, N. J.). 
Radiolabeling of Cells.  Leukemic spleen cells were washed with PBBS and then incubated for 
30-45 min at 37°C in PBBS. Cells were washed with PBBS and then resuspended in methionine- 
free Eagle's minimal essential media (Grand Island Biological Co., Grand Island, N. Y.) at 50 
×  106  cells/ml.  [35S]methionine  (978.4  Ci/mM;  New  England  Nuclear,  Boston  Mass.)  was 
added at a concentration of 100 #Ci/ml, and the cells were incubated at 37°C for 2 or 4 h. The 
cells were then washed twice with PBBS and lysed with lysing buffer (0.5% Nonidet-P-40 [NP- 
40] in 0.15 M sodium chloride and 0.01 M Tris-HC1, pH 7.2). The lysates were stored at -70°C 
before use. Leukemic spleen cells were labeled with [3H]glucosamine by incubating spleen cells 
at 50 ×  106 cells/ml in 3 ml of RPMI  1640,  10% FCS, 5 ×  10  -o M  2-mercaptoethanol (2-ME) 
plus 200 #Ci [3H]glueosamine (250-350 #Ci/mmol; New England Nuclear) for 16 h at 37°C. 
The cells were then washed twice with PBBS and lysed as above. Leukemic spleen cells were 
radioiodinated using carrier-free 125I (ICN  Nutritional  Bioehemicals, Cleveland, Ohio)  and 
Iodogen (Pierce Chemical Co., Rockford, Ill.). Leukemic spleen cells were washed twice with 
PBBS, erythrocytes were lysed as described above, and the cells were then washed three times 
with Dulbecco's modified PBS, pH 7.3. 20 ×  106 viable spleen cells in 1 ml of PBS were added 
to a  liquid scintillation counting vial containing 25  #g of Iodogen.  2  mCi  of ~25I was then 
added, and the vial was incubated for  10 min at 0°C.  The iodinated cells were washed once 
with cold PBS and lysed as above. 
Immunoprecipitation  and  Sodium  Dodecyl Sulfate-Polyacrylamide Gel  Electrophoresis  (SDS- 
PAGE).  The methods of immune precipitation using formalin-fixed S. aureus Cowan I strain 
and analysis of immune precipitates by SDS-PAGE using autoradiography have been described 
previously (12). 
Preparation of Cell Extracts.  The procedure for preparing NP-40-solubilized cell extracts has 
been described previously (12). The protein content of the individual extracts was determined 
by the method of Lowry et al. (14) and found to vary from 5 to  10 mg/ml. Productive virus 
infection of cell lines was monitored by measurement of reverse transcriptase in cell culture 
supernate as previously described (l 1). 
Cell-mediated Cytotoxicity.  The details of this 51Cr release assa~, have been previously reported 
(11).  Briefly, spleen cells from (C57BL/10Sn  ×  A.BY)F1 (H-2 /b) mice 14 d after inoculation 
with  1,000  FFU of FV were used as attacker cells. 1 ×  106 attacker cells and  1 ×  104 51Cr- 
labeled Y57 cells were added to flat-bottomed microtiter wells in 0.125  ml of RPMI  1640 plus 
15% FCS media. Cold target inhibitor cells were added at 3 ×  106, 1.5 X  106, 0.75 X  106, and 
0.37  ×  106 cells/well in 0.025  ml of RPMI  1640 plus 15% FCS. The trays were incubated at 
34°C for 19 h and sampled. The effector cells in this assay were positive for cell surface Thy-1 
antigen (15), as determined by sensitivity to anti-Thy-1 monoclonal antibody (16) and C. 
Results 
Analysis of Cell Surface FV Antigens on Early and Late Leukemic Spleen Cells Using Specific 
Antisera.  To  determine which  FV  cell surface antigens were  decreased on  late FV 
leukemic spleen cells, we compared the ability of late (30-60 d after virus inoculation) 
and early (8-10 d after virus FV inoculation) leukemic spleen cells to remove cytotoxic 
antibodies in goat antisera directed at env-encoded  gp70 and gag-encoded  p12.  gp70 
and p12 of RLV and FV share extensive antigenic reactivity; therefore, goat antisera 
raised against  RLV  proteins could  be used  to  detect  FV cell surface antigens  (12). WILLIAM J.  BRITT, JAMES  K.  COLLINS, AND  BRUCE  CHESEBRO  871 
Both early FV leukemic spleen ceils and late FV leukemic spleen cells appeared to 
express equal amounts of cell surface gp70; however, early FV leukemic spleen cells 
expressed fourfold more cell surface p12 antigen than late leukemic spleen cells,  as 
four times as many late leukemic cells were required to achieve a similar absorption 
of antibody (Fig.  1). These findings were confirmed with a  competitive radioimmu- 
noassay using 125I-gp70 or p12 (Fig.  2). 
Analysis of FV  Cell Surface Antigens on  Early and Late  Leukemic Spleen Cells Using 
Monoclonal Antibodies.  Mouse monoclonal antibodies reactive with F-MuLV proteins 
gp70 and gag-encoded p15 were used in indirect immunofluorescence to investigate 
further the cell surface antigens of early and late leukemic spleen cells. Previously we 
have  shown  that  monoclonal 48  was  highly specific  for  F-MuLV  gp70  and  that 
monoclonal 34 was likewise highly specific for Friend, Moloney, and Rauscher MuLV 
p15 (13). The majority of early FV leukemic spleen cells reacted both with anti-gp70 
and anti-pl5  monoclonal antibodies;  however,  late  FV  leukemic spleen  cells were 
indistinguishable from background immunofluoresence (Table I). These results indi- 
cated that late leukemic spleen cells expressed a  decreased amount of FV p15  cell 
surface antigens. Because p15 and p12 antigens are both encoded by the same viral 
gene and are expressed on the cell surface on the same polyprotein molecule (17,  18), 
these results agreed with those using goat anti-p 12 serum, indicating that expression 
of gag-encoded proteins was reduced on late leukemic cells.  However, in contrast to 
previous results with goat anti-gp70 serum, late leukemic spleen cells also expressed 
decreased F-MuLV gp70  as detected by monoclonal antibody. Because the mono- 
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FIG.  1.  Quantitative absorption of goat anti-RLV gp70 and goat anti-RLV p12 antisera by viable 
early and late leukemic spleen cells and normal spleen cells. The erythroleukemia cell line, AA41, 
was used as the SlCr-labeled target. 85 #1 of a  1:5,000  dilution of anti-gp70 or a  1:1,200  dilution of 
anti-pl2 was absorbed by increasing numbers of cells. Mean percent specific cytotoxicity values are 
shown with percent standard error normal spleen cells (O), early leukemic spleen cells (A), late 
leukemic spleen cells (I, 0). c~  c  o 
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Fie.  2.  The precipitation of I~I-RLV gp70 or 125I-RLV p12 by rabbit anti-RLV gp70 or rabbit 
anti-RLV p12  sera  was  determined  after preabsorption  of antisera  with  increasing numbers  of 
viable early and late leukemic spleen cells and normal spleen cells as demonstrated in competitive 
radioimmunoassay.  Normal spleen  cells (O), early leukemic spleen  cells (A), late leukemic spleen 
cells (m). 
TABLE  I 
Use of Hybridoma Antibodies  for Membrane Immunofluorescence Analysis of p 15 and gp 70 A ntzgens on 
Early and Late (BIO.A  ×  A/WySn)Fr Leukemia Cells 
First 
antibody  Second antibody 
Percent membrane immunofluorescent positive spleen 
cells 
30- to 60-d FV  Normal spleen  9-d leukemic  leukemic  cells 
None  FITC goat anti-mouse Ig  17 +  5  (10)*  11 ±  6 (17)  42 +  7 (7) 
34 (anti-plS)  FITC goat anti-mouse Ig  64 ±  12 (9)  16 ± 8 (12)  37 ±  7 (6) 
48 (anti-gp70)  FITC goat anti-mouse Ig  56 ±  11 (11)  16 ±  9 (17)  43 zt: 6 (7) 
* Average percent membrane fuorescence +  standard  deviation. Value in parenthesis  is the number of 
spleens studied. 
clonal  anti-gp70  was  specific  for  F-MuLV  gp70,  whereas  the  goat  antisera  cross- 
reacted with many  MuLV,  it appeared  that  late leukemic spleen cells might express 
an altered or new gp70 that was detected by the goat anti-gp70 serum and not by the 
monoclonal anti-F-MuLV  gp70. 
Characterization  of the gp70 Present on Late FV Leukemic Spleen Cells.  The cell surface 
proteins  of early and  late leukemic spleen cells were also studied  by immunoprecipi- 
tation  and  analysis  on  SDS-PAGE.  When  radioiodinated  leukemic spleen cells were 
precipitated  with goat anti-RLV  gp70,  a  70,000  mol wt and a  55,000  mol wt  protein 
were seen on both  early and  late  leukemia cells (Fig.  3).  In contrast,  mouse  anti-FV 
serum,  with predominant  reactivity for ecotropic F-MuLV,  precipitated  the gp70 on WILLIAM J.  BRITT, JAMES K.  COLLINS,  AND  BRUCE  CHESEBRO  873 
Ftc.  3.  SDS-PAGE  of 125I-labeled surface proteins of early (E) and late (L) leukemic spleen ceils. 
Approximately l0  s cell equivalents of lysate were immunoprecipitated with goat anti-RLV gp70, 
C57BL/10 anti-FV, or rabbit anti-FMCF sera. Immunoprecipitation of  I-normal spleen cells with 
these sera gave no detectable bands (data not shown). 
early  leukemic  cells  but  not  on  the  late  leukemic  cells  (Fig.  3).  Also,  monoclonal 
antibody  48,  which  recognized  only ecotropic  F-MuLV  gp70,  immunoprecipitated 
the  gp70 on early leukemic cells but not on late  leukemic cells  (data not shown).  In 
contrast,  the  gp70  on  late  leukemic  cells  was  precipitated  by a  rabbit  anti-FMCF 
serum  (Fig. 3). This reagent  had predominant  reactivity for FMCF-specific determi- 
nants,  and  it  failed  to precipitate  ecotropic  F-MuLV  gp70 on  early leukemic  cells. 
These results suggested that the gpTO on late leukemic spleen cells was different from 
ecotropic  F-MuLV  gp70.  To characterize  further  the  gp70 molecules  on  early  and 
late leukemic cells, we used extracts of nonradiolabeled F-MuLV-infected SC-1 ceils, 
FMCF-infected  mink cells,  and  xenotropic  MuLV-infected  mink  cells  to preabsorb 
the precipitating  antisera.  When  goat  anti-RLV  gp70 serum  was preabsorbed  with 
FMCF-infected or xenotropic MuLV-infected mink cell extracts,  the immunoprecip- 
itation of the gp70 on early leukemic spleen cells was not inhibited  (Fig. 4). Only F- 874  FRIEND MINK CELL FOCUS-INDUCING  VIRUS-LIKE gp70 
Fxo. 4.  SDS-PAGE  of a25I-labeled surface proteins of early leukemic spleen cells after immunopre- 
cipitation with preabsorbed goat anti-RLV gp70 serum. 5 #l of a 1:I00 dilution of goat anti-RLV 
gp70 serum was preabsorbed with (1) 200 ~l, (2) 100/xl, and (3) 20/,tl of extracts from cells infected 
with xenotropic MuLV, FMCF virus, and F-MuLV for 3 h at 0°C before addition of 125I-labeled 
cell lysates. The goat anti-gp70 serum was also preabsorbed with extracts from uninfected SC- 1  ceils 
(track A) or uninfected mink lung cells (track B). 
MuLV-infected SC-1 extracts inhibited the precipitation of the gp70 on early leukemic 
cells (Fig. 4). Therefore, as detected with goat anti-gp70 serum, early leukemic spleen 
cells  expressed  predominantly  ecotropic  F-MuLV  gp70.  When  the  gp70  on  late 
leukemic  cells  was  analyzed  in  a  similar  manner,  all  of the  infected  cell  extracts 
inhibited  the immune  precipitation  of gp70, indicating that  the precipitation  of the 
gp70  on  late  leukemic  cells  resulted  from  group-reacting  antibodies  present  in  the 
goat  anti-gp70  serum  (data  not  shown).  In  a  further  attempt  to  determine  the 
antigenic  nature  of the  gp70  on  late  leukemic  cells,  we  absorbed  the  rabbit  anti- 
FMCF serum with the nonradiolabeled virus-infected cell extracts. In this experiment, 
only FMCF-infected extracts prevented the immunoprecipitation  of the gp70 on late 
leukemic spleen cells  (Fig.  5).  Thus,  as detected  with  this  rabbit  anti-FMCF  serum, 
the  gp70 on late  leukemic  spleen  cells shared  antigenic  cross-reactivity with  FMCF 
only and not with F-MuLV or xenotropic MuLV. 
Late FV Leukemic Spleen Cells Exhibit  Decreased  Intracellular FV Precursor Proteins.  We 
have previously shown  that  late  leukemic cells not only expressed  decreased  surface WILLIAM J.  BRITT, JAMES K. COLLINS, AND BRUCE CHESEBRO  875 
FIc. 5.  SDS-PAGE  of 125I-labeled surface proteins of late leukemic  spleen cells after immunopre- 
cipitation with preabsorbed rabbit anti-FMCF serum. 5 #t of a 1:3 dilution of rabbit anti-FMCF 
serum was preabsorbed for 3 h at 0°C with (1) 200 #1, (2)  100 #1, or (3) 30 #1 of the same virus- 
infected cells extracts used in Fig. 4. Track A represents unabsorbed antiserum at a 1:3 dilution. 
antigens but also released 300-fold less infectious ecotropic F-MuLV (5). To determine 
whether this decrease in  release of infectious virus was associated with alteration  in 
viral  protein  synthesis,  early  and  late  leukemic  spleen  cells  were  labeled  with 
[~S]methionine,  and  immunoprecipitates  were  analyzed  by  SDS-PAGE.  The  env- 
encoded  (pr90,  pr80,  gp70)  and gag-encoded  (pr65,  p50,  p42)  intracellular  proteins 
were markedly decreased in late leukemic spleen cells as compared with early leukemic 
spleen  cells  (Fig.  6).  The  SFFV-encoded  protein,  gp55,  although  decreased on  late 
leukemic spleen cells, was readily detectable upon exposing the fluorograms for longer 
periods of time. In contrast, H-2 molecules were found in equal amounts in early and 
late leukemic spleens and in normal spleens (Fig. 6).  Furthermore, an equal number 
of acid precipitable counts per cell equivalent was present in the lysates of radiolabeled 
normal, early leukemic, and late leukemic spleen cells. Thus, the apparent decrease of 
viral proteins in late leukemic spleen cells was not secondary to a  general decrease in 
[SSS]methionine incorporation because H-2 and other proteins were similarly labeled 
in early and late leukemic cells. Because the gp70 of other MuLV have been associated 
with  a  larger (80,000-90,000  mol wt)  precursor protein  (12),  it was unclear why we 
initially could not demonstrate a larger precursor protein in late leukemic spleen cells. 
However, when a shorter labeling period was used and fluorograms were exposed for 
an  extended  time,  both  a  70,000  and  90,000  tool  wt  protein  were  observed  after 
precipitation with anti-gp70 serum (Fig. 7). Therefore, it appeared the gp70 antigens 
in  late  leukemic  cells  were  also  associated  with  a  probable  precursor  protein.  In 
addition,  when  radioiodinated  late  leukemic spleen  cells were immunoprecipitated 
with goat anti-gp70 serum and eluted in the absence of 2-ME, a 90,000 mol wt protein 
as well as the gp70 was present (Fig. 8). Thus, in nonreducing conditions, much of the 
gp70 in lysates of late cells appeared disulfide linked with a  smaller protein to form 876  FRIEND MINK CELL FOCUS-INDUCING  VIRUS-LIKE gp70 
Flc.  6.  SDS-PAGE  of [~S]methionine-labeled proteins from early (E) and late (L) leukemic spleen 
cells and  normal  (N)  spleen cells. Early  leukemic, late leukemic, or normal  spleen cells were 
radiolabeled with [3~S]methionine for 4 h and lysed as described in Materials and Methods. Equal 
numbers of cell equivalents and acid-precipitable counts per minute were immunoprecipitated with 
goat anti-RLV gp70, goat anti-RLV p 12, or mouse anti-H-2" antiserum. Fluorograms were exposed 
for 2 d. 
90,000 mol wt  complexes similar  to the disulfide  linkage of the gp70 and pl5E seen 
in MuLV virions after lysis in NP-40 (19). 
Anti-FV  Cytotoxic  T  Lymphocytes  (CTL)  Recognize  Late  FI/  Leukemic  Spleen 
Cells.  Previously  we  reported  that  late  FV  leukemic  spleen  cells  continued  to 
proliferate even in the presence of high levels of anti-FV cytotoxic antibody (4). This 
persistence of leukemia cells was correlated with the loss of cell surface virus-encoded 
antigens  and the apparent  resistance  of late leukemia cells to anti-FV  antibody and 
complement-mediated  destruction  (4).  In  addition,  we have  reported  that  anti-FV 
CTL apparently  recognized cell surface  F-MuLV-encoded gp70  (13).  To determine 
whether late leukemia cells also escaped recognition by anti-FV CTL because of their 
loss of cell  surface  F-MuLV  gp70,  we examined  the  ability  of late  leukemic  spleen 
cells to competitively inhibit  anti-FV CTL. As shown in Fig. 9, late leukemic spleen 
cells,  although  expressing  markedly  decreased  amounts  of  F-MuLV  gp70,  were WILLIAM J.  BRITT, JAMES  K. COLLINS, AND BRUCE CHESEBRO  877 
Flo.  7.  SDS-PAGE  of [aSS]methionine-labeled late leukemic spleen cells. After 2 h pulse labeling 
with [3SS]methionine, late leukemic  spleen cells were lysed as described in Materials and Methods, 
and lysates  were immunoprecipitated  with either goat anti-RLV gp70 or goat anti-RLV p12 serum. 
Fluorograms were exposed for 10 d. 
comparable with early FV leukemic spleen cells in their capacity to inhibit  anti-FV 
CTL. A total of 8 of 11 late leukemic spleens were found to be comparable with early 
leukemic spleens in their ability to inhibit anti-FV CTL. This finding suggested that 
late leukemic spleen cells were recognized by anti-FV  CTL even though  they were 
apparently resistant to antibody-complement-mediated lysis. 
Discussion 
The  results  presented  in  this  report  demonstrated  that  both  FV  env-  and  gag- 
encoded  antigens were decreased on  FV  leukemic spleen cells late  in  the  course of 
leukemia as compared with FV leukemic spleen cells early in the disease. This loss of 
cell surface antigens appeared to account for the previously reported resistance of late 
leukemic spleen cells to antibody-complement-mediated lysis (4). Initially, when early 
and  late  leukemic  spleen  cells  were  studied  with  heterologous  anti-gp70  antisera, 
either in quantitative absorption of cytotoxic antibody or in an RIA, we detected no 
difference in  the expression of FV  env cell surface antigens.  However, mouse mono- 
clonal antibody, which detected only ecotropic F-MuLV, revealed the loss of ecotropic 
F-MuLV gp70 from late leukemic spleen cells as compared with early leukemic spleen 
cells. Thus, it appeared that late leukemic spleen cells expressed a  new gp70 that was 
cross-reactive with the anti-gp70 antibodies present in the heterologous antisera. This 
finding was consistent with previous reports that have shown that heterologous goat 878  FRIEND  MINK  CELL  FOCUS-INDUCING  VIRUS-LIKE  gp70 
Fro.  8.  l~I-labeled  surface proteins of late  leukemic spleen cells were  immunoprecipitated with 
goat anti-RLV gp70 serum. Immunoprecipitates were eluted with (+ 2 ME) or without (- 2 ME) 
2-ME and analyzed in SDS-PAGE. 
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Fxc.  9.  Competitive inhibition of anti-FV CTL by early and late leukemic spleen cells and normal 
spleen cells. The erythroleukemia cell  line, Y57  (clone 2C),  was used as the 5XCr-labeled  target. 
Anti-FV CTL  were  inhibited  by  increasing numbers of normal spleen cells  (©),  early  leukemic 
spleen cells (A), and late leukemic spleen ceils (',  0). 
anti-gp70 sera often contained antibodies reactive not only with ecotropic F-MuLV 
gp70 but also with xenotropic MuLV gp70 and the SFFV-encoded gp55 (12, 20). 
The finding of a  cell surface gp70 on late leukemic cells, which  shared antigenic 
reactivity with FMCF, was unexpected. The origin of this new gp70 on late leukemic 
cells is uncertain.  Although  SFFV contains defective env  genomic sequences,  it does 
not express a gp70 on either the virion or infected ceils (20). Possibly, the gp70 on late WILLIAM J.  BRITT, JAMES K. COLLINS, AND BRUCE CHESEBRO  879 
cells could have arisen from a recombination between the helper F-MuLV and as yet 
unidentified virus(es). This possibility was supported by the finding that infection of 
baby mice with the helper F-MuLV alone resulted in the generation of recombinant 
MCF viruses (M. Cloyd, personal communication). 
The gp70 on late leukemic cells has not been associated with the release of infectious 
virus  or  RNA-dependent  DNA-polymerase-containing particles  (data  not  shown). 
Also, we have been unable to detect infectious MCF or xenotropic viruses in the virus 
stocks used for in vivo leukemia induction or in early spleen cells. The lack of release 
of infectious virus from late leukemic spleen cells could be the result of the lack of gag 
precursor  polyproteins  in  late  leukemic  spleen  cells.  Thus,  although  an  env  gene 
product is available for virion assembly, the necessary gag-encoded  structural proteins 
are not available for complete virion assembly. 
The significance of this  MCF-like gpT0 on late leukemic spleen cells is  unclear. 
Recently MCF viruses have been implicated in spontaneous leukemogenesis (21, 22). 
The  env  region  of some  MCF  viruses  appears  to  contain  the  necessary  genetic 
information  required  for  leukemia  induction  (23).  The  MCF-like  gp70  on  late 
leukemia cells suggested the possibility that  neoplastic transformation  of erythroid 
cells in this disease may have been initiated by a recombinant MCF virus rather than 
by SFFV. This possibility was supported by reports of erythroleukemia induction in 
baby  mice  by  F-MuLV  in  the  absence  of SFFV  (24).  Although  the  continued 
malignant  phenotype of late  leukemic  spleen  cells  and  the  appearance  of a  new 
nonecotropic gp70 seemed a more than coincidental finding, the possibility that this 
gp70 may be present on late leukemic cells as the result of an arrest at a  particular 
stage of differentiation must also be considered. Other workers have identified MuLV 
gpT0 on normal cells (25). The GIx antigen, originally defined as an alloantigen on 
normal thymocytes of certain mouse strains, was subsequently shown to be located on 
a MuLV gpT0 molecule (26). 
Cell  surface  protein  labeling  with  125I as  well  as  metabolic  labeling  with  [35S]- 
methionine revealed the presence of the SFFV protein, gp55, on both early and late 
leukemic spleen cells. Further evidence of continued SFFV expression in late leukemic 
spleen cells was obtained by our finding that reinfection of late leukemic spleen cells 
with competent helper F-MuLV  in vitro resulted in the quantitative rescue of the 
defective SFFV  (W.  Britt  and  B. Chesebro, manuscript  in  preparation).  Thus, the 
expression  of SFFV  on  late  leukemic  spleen  cells  appeared  to  be  under  separate 
control from the expression of the helper F-MuLV. It is possible that the continued 
expression of gp55 may result from the lack of a  humoral immune response to this 
protein in these mouse strains (13). 
We have reported that high levels of cytotoxic anti-FV antibody not only reduced 
the expression of cell surface FV antigens on leukemic spleen cells, but also dramati- 
cally decreased the release of infectious virus (5). [a6S]Methionine metabolic labeling 
followed by  immune  precipitation  and  analysis  on  SDS-PAGE  revealed that  late 
leukemic spleen cells expressed drastically reduced amounts of intracellular F-MuLV 
viral polyprotein precursors as compared with early leukemic spleen cells.  Exposure 
of leukemia cells to cytotoxic antiviral antibody appeared to mediate these changes in 
both intracellular and cell surface proteins because transfer of late leukemia cells into 
mice lacking antibodies resulted in reexpression of helper virus proteins and release of 
infectious virus (5).  Similarly, Fujamini and Oldstone (27)  have reported that  anti- 880  FRIEND  MINK CELL  FOCUS-INDUCING VIRUS-LIKE gp70 
measles antibody not only reduced cell surface expression of measles antigens but also 
markedly reduced the production of intracellular measles proteins. Also, Yagi et al. 
(28) described the loss of infectious virion release and the marked alteration of virion 
glycoproteins in a mouse mammary tumor virus-induced cell line exposed to cytotoxic 
anti-MMTV  antibody  and  immune  spleen  cells.  The  mechanism  of cell  surface 
antibody-induced alteration  of intracellular  viral  precursor protein  production  re- 
mains unknown. Potential mechanisms might include antibody-induced cell surface 
viral protein redistribution with the subsequent disruption of virion assembly. Intra- 
cellular virion components could then accumulate, leading to the feedback inhibition 
of viral protein synthesis. Although such a speculative mechanism could explain our 
observations, another equally likely explanation could be the selection and overgrowth 
of a population of virus nonproducer cells as a result of the immune pressure exerted 
by cytotoxic anti-FV antibody. Our preliminary experiments with passive transfer of 
monoclonal  anti-FV  antibodies  suggest  that  both  mechanisms  may  be  operating 
simultaneously in this system (W. Britt and B. Chesebro, manuscript in preparation). 
Other investigators have suggested that cell surface antigen loss induced by antiviral 
antibody might protect infected cells from virus-specific cell-mediated lysis (29). This 
did not appear to be the case in the FV system. Our findings indicated that anti-FV 
CTL could  recognize late  leukemic  spleen  cells  even  though  these  cells  expressed 
much  decreased  amounts  of F-MuLV  cell  surface  antigens.  This  result  could  be 
interpreted to suggest that anti-FV CTL may recognize antigens other than F-MuLV 
cell surface proteins,  such  as  SFFV-encoded antigens  (30).  However, our previous 
results with cloned mutant erythroleukemia cells suggested that F-MuLV gp70 was 
the main target for anti-FV CTL (11).  Therefore, it appeared more likely that these 
CTL were able to recognize residual low amounts of F-MuLV gp70 on late leukemic 
ceils (31, 32). Alternatively, it was also possible that anti-FV CTL could detect cross- 
reactivity between the original F-MuLV gp70 and the new MCF-like gp70 on these 
leukemic  cells.  Because  late  leukemic  cells  with  antibody-induced  decreased  cell 
surface antigens were recognized by anti-FV CTL, the lack of recovery from leukemia 
in  H-2  ~/a Rfv-3  r/s mice appeared  to be a  result of lack of sufficient anti-FV  CTL 
rather than to modulation or removal of CTL target antigens by anti-FV antibody. 
Summary 
Spleen cells from  Rfv-3  r/s mice with  Friend virus-induced erythroleukemia were 
analyzed for expression of virus-induced proteins with monoclonal antiviral antibodies 
and  conventional antisera.  Leukemic spleen  cells,  30-60  d  after virus  inoculation, 
expressed decreased amounts of ecotropic Friend murine leukemia helper virus gag- 
and env-encoded cell surface and intracellular proteins compared with leukemic cells 
tested  8-10  d  after virus  inoculation.  In  contrast,  the  spleen  focus-forming virus- 
induced protein, gp55, was present on both leukemia cell populations. This difference 
appeared to be mediated by the humoral antibody response in Rfv-3  r/s mice, which 
could  recognize only ecotropic gag  and  env  proteins,  and  not  gp55.  A  new  gp70 
molecule cross-reactive with a recombinant Friend mink cell focus-inducing virus was 
found in large quantities on late leukemic cells.  This protein appeared to be derived 
from a recombinant virus produced during the course of Friend virus infection. The 
appearance  of this  new  gp70  suggests  that  recombinant  viruses  other  than  spleen 
focus-forming virus may play a role in Friend virus-induced erythroleukemia. WILLIAM J.  BRITT, JAMES  K.  COLLINS, AND BRUCE  CHESEBRO  881 
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